Aeglea BioTherapeutics (NASDAQ: AGLE)
$32.99
(-3.7%)
-$1.26
Price as of April 24, 2024, 4:00 p.m. ET
Aeglea BioTherapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Aeglea BioTherapeutics Company Info
Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
News & Analysis
Featured Article
3 Biotech Stocks That Sank: Are Any a Bad-News Buy?
At least one of the three could be in store for better news in the future.
Keith Speights and Brian Orelli, PhD | Dec 17, 2021
Featured Article
Why Aeglea BioTherapeutics Stock Is Way Down Today
MIxed phase 3 clinical trial results are making investors nervous.
Cory Renauer | Dec 6, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.